{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:27:33Z","timestamp":1794328053198,"version":"4.9.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication of hematopoietic stem cell or solid organ transplantation. Current prognostic tools for PTLD lack sufficient precision in predicting treatment response. This prospective feasibility study evaluates circulating tumor DNA (ctDNA) for risk stratification and treatment monitoring in PTLD. Plasma samples (n = 86) from 27 patients (13 positive for Epstein-Barr virus [EBV] positive and 14 EBV negative) were analyzed using targeted 115-gene sequencing and low-coverage whole-genome sequencing at diagnosis, after rituximab treatment and\/or chemotherapy, and at end of treatment (EOT). At baseline, somatic single-nucleotide variants were detected in all patients. Multinucleotide variants were mostly detected in the B-cell lymphoma 6 superenhancer hypermutation region, especially in EBV-negative patients. Copy number variants were detected in 13 of 27 patients. An elevated ctDNA level at baseline indicated a poor outcome of rituximab monotherapy, and an undetectable ctDNA level at interim was correlated with better response. Seven patients showed completely undetectable ctDNA levels, whereas positron emission tomography\u2013computed tomography (PET\/CT) scan indicated active disease at interim; all 7 patients reached complete metabolic response by EOT. We demonstrate that ctDNA could potentially be used for prognostication and disease monitoring in PTLD, outperforming PET\/CT in 8 patients. This indicates that ctDNA monitoring can complement PET\/CT to guide early escalation to chemotherapy in high-risk patients, although larger cohorts are needed to validate these findings. This trial was registered at the Dutch Trial Register as NTR7402.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018879","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:56:43Z","timestamp":1787777803000},"page":"7271-7280","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Molecular profiling and disease tracking of posttransplant lymphoproliferative disorders using cell-free DNA"],"prefix":"10.1182","volume":"10","author":[{"given":"Yujie","family":"Zhong","sequence":"first","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"},{"name":"2Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2635-3528","authenticated-orcid":false,"given":"Nick","family":"Veltmaat","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Montes de Jesus","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens","family":"Sillje","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"},{"name":"2Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier","family":"Mous","sequence":"additional","affiliation":[{"name":"3Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-9182","authenticated-orcid":false,"given":"Martine E. D.","family":"Chamuleau","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne H.","family":"Tonino","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim G. N. J.","family":"Mutsaers","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Erasmus University Medical Center, Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein W. M.","family":"van der Poel","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy B. C.","family":"Stevens","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Radboud University Medical Center, Radboud University, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A. M.","family":"Verschuuren","sequence":"additional","affiliation":[{"name":"8Groningen Institute for Organ Transplantation, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7650-2937","authenticated-orcid":false,"given":"Joost","family":"Kluiver","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"van den Berg","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9828-9460","authenticated-orcid":false,"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-1050","authenticated-orcid":false,"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[{"name":"1Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,29]]},"reference":[{"key":"2026111011021923000_bib1","author":"WHO Classification of Tumours Editorial Board","year":"2024","edition":"5th edition"},{"key":"2026111011021923000_bib2","author":"Samant","year":"2025"},{"issue":"5","key":"2026111011021923000_bib3","first-page":"804","article-title":"Admissions for posttransplant lymphoproliferative disorder: a 9-year longitudinal analysis of the National (Nationwide) Inpatient Sample","volume":"37","author":"El-Amir","year":"2024","journal-title":"Proc"},{"issue":"5","key":"2026111011021923000_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy","volume":"11","author":"Nourse","year":"2011","journal-title":"Am J Transplant"},{"issue":"2","key":"2026111011021923000_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.onc.1209023","article-title":"LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice","volume":"25","author":"Thornburg","year":"2006","journal-title":"Oncogene"},{"issue":"5438","key":"2026111011021923000_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1126\/science.286.5438.300","article-title":"Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses","volume":"286","author":"Uchida","year":"1999","journal-title":"Science"},{"issue":"12","key":"2026111011021923000_bib7","first-page":"8225","article-title":"Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10","volume":"179","author":"Lambert","year":"2007","journal-title":"J Immunol 1950"},{"issue":"2","key":"2026111011021923000_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ajt.13558","article-title":"EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features","volume":"16","author":"Ferreiro","year":"2016","journal-title":"Am J Transplant"},{"issue":"3","key":"2026111011021923000_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/modpathol.2016.199","article-title":"Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma","volume":"30","author":"Morscio","year":"2017","journal-title":"Mod Pathol"},{"issue":"3","key":"2026111011021923000_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/PDM.0b013e31804f54a9","article-title":"Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders","volume":"16","author":"Craig","year":"2007","journal-title":"Diagn Mol Pathol"},{"issue":"8","key":"2026111011021923000_bib11","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/cncr.21391","article-title":"Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial","volume":"104","author":"Blaes","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"2026111011021923000_bib12","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"issue":"11","key":"2026111011021923000_bib13","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3324\/haematol.11360","article-title":"Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease","volume":"92","author":"Gonz\u00e1lez-Barca","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"2026111011021923000_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-020-04056-9","article-title":"Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients","volume":"100","author":"Gonz\u00e1lez-Barca","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"2026111011021923000_bib15","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41375-022-01667-1","article-title":"Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial","volume":"36","author":"Zimmermann","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2026111011021923000_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026111011021923000_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/2040620711412417","article-title":"Therapeutic options in post-transplant lymphoproliferative disorders","volume":"2","author":"Zimmermann","year":"2011","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"2026111011021923000_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07149.x","article-title":"A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation","volume":"141","author":"Hourigan","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"2026111011021923000_bib19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","article-title":"Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders","volume":"19","author":"Leblond","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026111011021923000_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Choquet","year":"2007","journal-title":"Ann Hematol"},{"issue":"30","key":"2026111011021923000_bib21","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026111011021923000_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13550-021-00769-8","article-title":"Prognostic superiority of International Prognostic Index over [18F]FDG PET\/CT volumetric parameters in post-transplant lymphoproliferative disorder","volume":"11","author":"Montes de Jesus","year":"2021","journal-title":"EJNMMI Res"},{"issue":"1","key":"2026111011021923000_bib23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-023-01500-x","article-title":"Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA","volume":"16","author":"Veltmaat","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2026111011021923000_bib24","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"issue":"364","key":"2026111011021923000_bib25","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"2026111011021923000_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","article-title":"Inferring gene expression from cell-free DNA fragmentation profiles","volume":"40","author":"Esfahani","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"22","key":"2026111011021923000_bib27","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"27","key":"2026111011021923000_bib28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026111011021923000_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7920","key":"2026111011021923000_bib30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41586-022-04906-8","article-title":"Super-enhancer hypermutation alters oncogene expression in B cell lymphoma","volume":"607","author":"Bal","year":"2022","journal-title":"Nature"},{"key":"2026111011021923000_bib31","author":"Vasimuddin","year":"20-24  2019"},{"issue":"5","key":"2026111011021923000_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat Genet"},{"issue":"9","key":"2026111011021923000_bib33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"issue":"12","key":"2026111011021923000_bib34","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1101\/gr.175141.114","article-title":"DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly","volume":"24","author":"Scheinin","year":"2014","journal-title":"Genome Res"},{"issue":"1","key":"2026111011021923000_bib35","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"2026111011021923000_bib36","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00277-025-06328-8","article-title":"Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics","volume":"104","author":"Veltmaat","year":"2025","journal-title":"Ann Hematol"},{"issue":"3","key":"2026111011021923000_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/gcc.20287","article-title":"Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities","volume":"45","author":"Djokic","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2026111011021923000_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bjh.14633","article-title":"Mutational landscape of B-cell post-transplant lymphoproliferative disorders","volume":"178","author":"Menter","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"2026111011021923000_bib39","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/01.pas.0000213317.59176.d2","article-title":"Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study","volume":"30","author":"Johnson","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2026111011021923000_bib40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"28","key":"2026111011021923000_bib41","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026111011021923000_bib42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/JCO-25-01712","article-title":"Prospective validation of circulating tumor DNA measurable residual disease after first-line therapy in large B-cell lymphoma","volume":"44","author":"Wang","year":"2026","journal-title":"J Clin Oncol"},{"issue":"34","key":"2026111011021923000_bib43","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO-25-01534","article-title":"Remission assessment by circulating tumor DNA in large B-cell lymphoma","volume":"43","author":"Roschewski","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/21\/7271\/2597408\/blooda_adv-2025-018879-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/21\/7271\/2597408\/blooda_adv-2025-018879-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:02:25Z","timestamp":1794326545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/21\/7271\/570539\/Molecular-profiling-and-disease-tracking-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,29]]},"references-count":43,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018879","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,10]]},"published":{"date-parts":[[2026,10,29]]}}}